Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Recombinant adenovirus type 5 + Iparomlimab/Tuvonralimab with standard therapy in soft tissue sarcoma
ChiCTR2600120464Phase 2Not yet recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Mar 2026
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, Gene Therapies, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Oncorine, iparomlimab and tuvonralimab in soft tissue sarcoma (STS), sponsored by Zhongshan Hospital, Fudan University. Primary endpoint: Objective response rate in the virus injection area. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
Oncorineiparomlimabtuvonralimab
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on ChiCTR2600120464.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600120464.